We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+35.53%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.48B
AUM Growth
+$248M
Cap. Flow
-$7.45M
Cap. Flow %
-0.5%
Top 10 Hldgs %
45.09%
Holding
80
New
10
Increased
13
Reduced
36
Closed
16

Top Buys

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$41.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$30.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$28.9M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$27M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$66.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$37.2M
4
TBPH icon
Theravance Biopharma
TBPH
+$22.6M
5
ARGX icon
argenx
ARGX
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.33%
2 Miscellaneous 5.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
1
InflaRx
IFRX
$296M
$97.9M 6.62%
2,590,000
+1,114,860
+76% +$41.5M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.5B
$83.8M 5.66%
+925,000
New +$78.7M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$78.8M 5.33%
1,075,000
-676,699
-39% -$46M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.2B
$70.6M 4.77%
600,000
+261,544
+77% +$22.9M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$70.2M 4.74%
3,600,000
-902,498
-20% -$14.2M
ANAB icon
6
AnaptysBio
ANAB
$1.6B
$67.2M 4.54%
920,000
-185,557
-17% -$12.8M
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$56.6M 3.83%
1,100,000
+450,000
+69% +$19.4M
RETA
8
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$52.6M 3.55%
615,000
-59,251
-9% -$4.92M
PRNB
9
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$48M 3.24%
1,411,898
-62,464
-4% -$1.99M
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
$41.4M 2.8%
115,000
-4,069
-3% -$1.43M
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$39M 2.64%
1,009,586
+277,965
+38% +$6.48M
BPMC
12
DELISTED
Blueprint Medicines
BPMC
$36M 2.43%
450,000
+88,649
+25% +$6.55M
SRPT icon
13
Sarepta Therapeutics
SRPT
$2.14B
$35.8M 2.42%
300,000
+210,000
+233% +$27M
CCXI
14
DELISTED
ChemoCentryx, Inc.
CCXI
$35.1M 2.37%
+2,525,900
New +$28.9M
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$35M 2.36%
+300,000
New +$30.2M
ARGX icon
16
argenx
ARGX
$61.5B
$34.3M 2.32%
275,000
-175,000
-39% -$20.6M
CRSP icon
17
CRISPR Therapeutics
CRSP
$5.09B
$32.1M 2.17%
900,000
+800,000
+800% +$27.7M
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$31.2M 2.11%
600,000
-77,451
-11% -$3.57M
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
$30.5M 2.06%
1,272,495
-13,333
-1% -$242K
ALLK
20
DELISTED
Allakos
ALLK
$30.4M 2.05%
750,000
+600,000
+400% +$24.2M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$384M
$29.8M 2.02%
1,700,000
-245,659
-13% -$3.88M
AUTL
22
Autolus Therapeutics
AUTL
$516M
$26.8M 1.81%
+850,000
New +$24.2M
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
$24.8M 1.67%
450,000
-61,395
-12% -$2.92M
KURA icon
24
Kura Oncology
KURA
$1.01B
$23.2M 1.57%
1,400,000
+850,000
+155% +$13.1M
KZR
25
DELISTED
Kezar Life Sciences
KZR
$23.1M 1.56%
130,000
-12,291
-9% -$2.42M
1
2 3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Cormorant Asset Management held 80 positions worth $1.48B, up 20% from $1.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management's Q1 2019 filing shows 10 new, 13 increased, 36 reduced and 16 closed positions. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 300,000 shares worth $35M. The largest sale was TESARO, Inc., an estimated $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q1 2019 buy was Lakefront Biotherapeutics American Depositary Shares: 300,000 shares worth $35M.
  • Cormorant Asset Management added most to InflaRx in Q1 2019, an estimated $41.5M increase.
  • Cormorant Asset Management's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $66.8M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.48B portfolio in Q1 2019.
  • Cormorant Asset Management opened 10 new positions and closed 16 in Q1 2019.
  • Cormorant Asset Management's portfolio value rose 20% quarter-over-quarter to $1.48B.

Based on Cormorant Asset Management's 13F filing for Q1 2019, filed 15 May 2019.